Enerzair Breezhaler ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - drogy obštrukčnej choroby dýchacích ciest, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.